Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Srdan Verstovsek; Francesco Passamonti; Alessandro Rambaldi; Giovanni Barosi; Elisa Rumi; Elisabetta Gattoni; Lisa Pieri; Huiling Zhen; Muriel Granier; Albert Assad; Mario Cazzola; Hagop M. Kantarjian; Tiziano Barbui; Alessandro M. Vannucchi

doi:10.1182/blood-2017-02-765032

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Huiling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi

Leukemia

Research output: Contribution to journal › Letter › peer-review

44 Scopus citations

Original language	English (US)
Pages (from-to)	1768-1771
Number of pages	4
Journal	Blood
Volume	130
Issue number	15
DOIs	https://doi.org/10.1182/blood-2017-02-765032
State	Published - Oct 12 2017

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/blood-2017-02-765032

Cite this

Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rumi, E., Gattoni, E., Pieri, L., Zhen, H., Granier, M., Assad, A., Cazzola, M., Kantarjian, H. M., Barbui, T., & Vannucchi, A. M. (2017). Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 130(15), 1768-1771. https://doi.org/10.1182/blood-2017-02-765032

Verstovsek, S, Passamonti, F, Rambaldi, A, Barosi, G, Rumi, E, Gattoni, E, Pieri, L, Zhen, H, Granier, M, Assad, A, Cazzola, M, Kantarjian, HM, Barbui, T & Vannucchi, AM 2017, 'Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results', Blood, vol. 130, no. 15, pp. 1768-1771. https://doi.org/10.1182/blood-2017-02-765032

@article{d1cf56b3a7c44c31be296f7105a7f4c7,

title = "Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results",

author = "Srdan Verstovsek and Francesco Passamonti and Alessandro Rambaldi and Giovanni Barosi and Elisa Rumi and Elisabetta Gattoni and Lisa Pieri and Huiling Zhen and Muriel Granier and Albert Assad and Mario Cazzola and Kantarjian, {Hagop M.} and Tiziano Barbui and Vannucchi, {Alessandro M.}",

note = "Funding Information: This work was supported by a cancer center support grant from the National Cancer Institute of the National Institutes of Health (P30 CA016672) through the MD Anderson Cancer Center. The work in Varese, Italy, was supported by AIL-Varese Onlus. The work in Florence and in Pavia, Italy, was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (progetto AGIMM 5 per mille, no. 1005) to A.M.V. and M.C., respectively. Cory Pfeiffenberger{\textquoteright}s work (Complete Healthcare Communications, LLC) was funded by Incyte Corporation. The respective institutions of S.V., F.P., A.R., G.B., E.R., E.G., L.P., M.C., H.M.K., T.B., and A.M.V. received research funding from Incyte Corporation for the conducting of this study. Study INCB18424-256 was sponsored by Incyte Corporation, Wilmington, DE. Funding Information: Conflict-of-interest disclosure: S.V. has participated in advisory boards for Incyte Corporation. F.P. has participated in advisory boards for and received honorariafromNovartis.H.Z.,M.G.,andA.A.areemployeesofIncyteCorporation. A.M.V. has participated in advisory boards for and received honoraria and research funding from Novartis. The remaining authors declare no competing financial interests.",

year = "2017",

month = oct,

day = "12",

doi = "10.1182/blood-2017-02-765032",

language = "English (US)",

volume = "130",

pages = "1768--1771",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "15",

}

TY - JOUR

T1 - Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea

T2 - long-term phase 2 study results

AU - Verstovsek, Srdan

AU - Passamonti, Francesco

AU - Rambaldi, Alessandro

AU - Barosi, Giovanni

AU - Rumi, Elisa

AU - Gattoni, Elisabetta

AU - Pieri, Lisa

AU - Zhen, Huiling

AU - Granier, Muriel

AU - Assad, Albert

AU - Cazzola, Mario

AU - Kantarjian, Hagop M.

AU - Barbui, Tiziano

AU - Vannucchi, Alessandro M.

N1 - Funding Information: This work was supported by a cancer center support grant from the National Cancer Institute of the National Institutes of Health (P30 CA016672) through the MD Anderson Cancer Center. The work in Varese, Italy, was supported by AIL-Varese Onlus. The work in Florence and in Pavia, Italy, was supported by a grant from the Associazione Italiana per la Ricerca sul Cancro (progetto AGIMM 5 per mille, no. 1005) to A.M.V. and M.C., respectively. Cory Pfeiffenberger’s work (Complete Healthcare Communications, LLC) was funded by Incyte Corporation. The respective institutions of S.V., F.P., A.R., G.B., E.R., E.G., L.P., M.C., H.M.K., T.B., and A.M.V. received research funding from Incyte Corporation for the conducting of this study. Study INCB18424-256 was sponsored by Incyte Corporation, Wilmington, DE. Funding Information: Conflict-of-interest disclosure: S.V. has participated in advisory boards for Incyte Corporation. F.P. has participated in advisory boards for and received honorariafromNovartis.H.Z.,M.G.,andA.A.areemployeesofIncyteCorporation. A.M.V. has participated in advisory boards for and received honoraria and research funding from Novartis. The remaining authors declare no competing financial interests.

PY - 2017/10/12

Y1 - 2017/10/12

UR - http://www.scopus.com/inward/record.url?scp=85031279344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031279344&partnerID=8YFLogxK

U2 - 10.1182/blood-2017-02-765032

DO - 10.1182/blood-2017-02-765032

M3 - Letter

C2 - 28827411

AN - SCOPUS:85031279344

SN - 0006-4971

VL - 130

SP - 1768

EP - 1771

JO - Blood

JF - Blood

IS - 15

ER -

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this